Background: Undifferentiated pleomorphic sarcoma of the extremity and trunk (ET-UPS) presents a unique therapeutic challenge. Although immunotherapy has recently been employed in advanced soft tissue sarcoma, there is limited data characterizing the immune infiltrate in ET-UPS. Radiotherapy (RT) has been shown in other tumor types to promote tumor antigen release and enhance tumor-specific targeting by the adaptive immune system. The aim of this study was to 1) characterize the baseline immune infiltrate and 2) evaluate the effect of preoperative RT on the histologic appearance of and the immune infiltrate in ET-UPS. Methods: We identified 17 matched ET-UPS samples before and after RT. Immunohistochemistry was performed with CD8, CD4, PD-L1, PD1, CD3, CD163 and FoxP3 positive cells identified in all samples. Changes in the immune infiltrate following RT were examined. Results: There was a trend towards increased density of tumor infiltrating immune cells in ET-UPS following RT, with increases in median number of CD3 (158 vs 219 cells/mm2, p = 0.06), CD4 (3 vs 13 cells/mm2, p = 0.01), CD8 (55 vs 111 cells/mm2, p = 0.17), and FOXP3 (14 vs 25 cells/mm2, p = 0.23) positive cells. Interestingly, although PD-L1 was not expressed in any ET-UPS tumor at baseline, positive PD-L1 expression was observed in 21% (3/14) of tumors after RT (p = 0.07). Conclusion: An immune infiltrate is present in ET-UPS at the time of diagnosis, with a trend towards increased density of immune infiltrate and PD-L1 expression after RT. These data support prospectively evaluating immune checkpoint inhibitors with standard of care RT in the treatment of ET-UPS.
Background: Undifferentiated pleomorphic sarcoma of the extremity and trunk (ET-UPS) presents a unique therapeutic challenge. Although immunotherapy has recently been employed in advanced soft tissue sarcoma, there is limited data characterizing the immune infiltrate in ET-UPS. Radiotherapy (RT) has been shown in other tumor types to promote tumor antigen release and enhance tumor-specific targeting by the adaptive immune system. The aim of this study was to 1) characterize the baseline immune infiltrate and 2) evaluate the effect of preoperative RT on the histologic appearance of and the immune infiltrate in ET-UPS. Methods: We identified 17 matched ET-UPS samples before and after RT. Immunohistochemistry was performed with CD8, CD4, PD-L1, PD1, CD3, CD163 and FoxP3 positive cells identified in all samples. Changes in the immune infiltrate following RT were examined. Results: There was a trend towards increased density of tumor infiltrating immune cells in ET-UPS following RT, with increases in median number of CD3 (158 vs 219 cells/mm2, p = 0.06), CD4 (3 vs 13 cells/mm2, p = 0.01), CD8 (55 vs 111 cells/mm2, p = 0.17), and FOXP3 (14 vs 25 cells/mm2, p = 0.23) positive cells. Interestingly, although PD-L1 was not expressed in any ET-UPS tumor at baseline, positive PD-L1 expression was observed in 21% (3/14) of tumors after RT (p = 0.07). Conclusion: An immune infiltrate is present in ET-UPS at the time of diagnosis, with a trend towards increased density of immune infiltrate and PD-L1 expression after RT. These data support prospectively evaluating immune checkpoint inhibitors with standard of care RT in the treatment of ET-UPS.
Authors: J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Theodore S Nowicki; Ryan Akiyama; Rong Rong Huang; I Peter Shintaku; Xiaoyan Wang; Paul C Tumeh; Arun Singh; Bartosz Chmielowski; Christopher Denny; Noah Federman; Antoni Ribas Journal: Cancer Immunol Res Date: 2016-12-30 Impact factor: 11.151
Authors: John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen Journal: Cancer Date: 2014-07-31 Impact factor: 6.860
Authors: C Messiou; S Bonvalot; A Gronchi; D Vanel; M Meyer; P Robinson; C Morosi; J L Bloem; P H Terrier; A Lazar; C Le Péchoux; E Wardelman; J M Winfield; B Boulet; J Bovée; R L Haas Journal: Eur J Cancer Date: 2016-01-20 Impact factor: 9.162
Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi Journal: Clin Cancer Res Date: 2020-01-03 Impact factor: 12.531
Authors: Laurene S Cheung; Lingling Chen; Teniola F Oke; Thomas B Schaffer; Karim Boudadi; Jillian T Ngo; John McMahon Gross; Holly Kemberling; Luis A Diaz; Evan Lipson; John-WIlliam Sidhom; Janis Taube; Robert Anders; Drew M Pardoll; Dung T Le; Christian F Meyer; Nicolas Llosa Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Kripa Guram; Maria Nunez; John Einck; Loren K Mell; Ezra Cohen; P Dominick Sanders; Sayuri Miyauchi; Elizabeth Weihe; Razelle Kurzrock; Sarah Boles; Andrew B Sharabi Journal: Front Oncol Date: 2018-10-17 Impact factor: 6.244
Authors: Emily Z Keung; Alexander J Lazar; Keila E Torres; Wei-Lien Wang; Janice N Cormier; B Ashleigh Guadagnolo; Andrew J Bishop; Heather Lin; Kelly K Hunt; Justin Bird; Valerae O Lewis; Shreyaskumar R Patel; Jennifer A Wargo; Neeta Somaiah; Christina L Roland Journal: BMC Cancer Date: 2018-09-24 Impact factor: 4.430